Biblio

Export 17 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Keyword is A and Author is Fox, Nick C  [Clear All Filters]
2018
P. G. Kehoe, Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., Coulthard, E., Passmore, A. Peter, Fox, N. C., Wilkinson, I. B., and Ben-Shlomo, Y., “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
P. G. Kehoe, Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., Coulthard, E., Passmore, A. Peter, Fox, N. C., Wilkinson, I. B., and Ben-Shlomo, Y., “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
P. G. Kehoe, Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., Coulthard, E., Passmore, A. Peter, Fox, N. C., Wilkinson, I. B., and Ben-Shlomo, Y., “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
P. G. Kehoe, Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., Coulthard, E., Passmore, A. Peter, Fox, N. C., Wilkinson, I. B., and Ben-Shlomo, Y., “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
2016
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
2014
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
2011
M. S. Albert, DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., and Phelps, C. H., “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.